1.	Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NU 10L01, STU00038215, NCT01259089
2.	AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CAUY922ZN11, NCT01361945
3.	A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAUY922A2206, 2010-020116-11, NCT01124864
4.	A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 20 to 75 Sponsor: Other Protocol IDs: T2211, NCT01389583
5.	Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAUY922A2205, 2011-002570-23, NCT01402401
6.	Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCRI GI 148, NCT01404650
7.	Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DDP-922, NCT01484860
8.	A Study of the HSP90 Inhibitor AUY922 Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-0467, NCT01485536
9.	An Phase II Study to Evaluate the Efficacy of AUY922 Versus Pemetrexed or Docetaxel in Non Small Cell Lung Cancer Patients With EGFR Mutations Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAUY922A2207, 2012-001050-25, NCT01646125
10.	HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 12-076, NCT01668173
11.	Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CAUY922AUS06T, NCT01294826
12.	Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 75 and over Sponsor: NCI, Other Protocol IDs: CASE3Y10, NCI-2011-03107, NCT01602627
13.	PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBYL719X2103, 2011-005978-40, NCT01613950